AMEX EXTENDS LISTING TO MARCH 31, 2006
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of
Report (Date of Earliest Event Reported):
December 8, 2005
Commission
File No. 1-14778
DOR
BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its charter)
|
DELAWARE
|
|
41-1505029
|
|
(State
or other jurisdiction of incorporation or organization)
|
|
(I.R.S.
Employer Identification Number)
|
| |
|
|
|
1691
Michigan Ave., Suite 435
Miami,
FL
|
|
33139
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
| |
(305)
534-3383
|
|
| |
(Issuer’s
telephone number, including area code)
|
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[
]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
[
]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item 3.01.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Transfer of Listing.
On
December 8, 2005 the Company received
notice from the American Stock Exchange (“AMEX”) that after a hearing on
December 2 with a Listing Qualifications Panel of the Amex Committee on
Securities (“the Panel”), it has been granted an extension within which to
regain compliance with the continued listing standards of the AMEX.
Based
on
the presentation of DOR management at that meeting,
the
Panel unanimously agreed to grant DOR until March 31, 2006 to regain compliance
with the continued listing standard of Section 1003 (a)(iii) of the AMEX Company
Guide. This standard requires that member companies that have incurred losses
in
their five most recent fiscal years must maintain a shareholder equity balance
of at least $6,000,000. If the Company has not achieved the minimum shareholder
equity requirement by March 31, 2006, the Panel unanimously agreed that the
AMEX
should immediately move to delist the Company’s common stock at that time with
no further opportunity for the Company to appeal.
Item
9.01. Financial Statements and Exhibits.
(c)
Exhibits.
Exhibit
No. Title
99.1 Press
Release issued by the Company dated December 9, 2005.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
DOR
BIOPHARMA,
INC.
By:
/s/
Michael T. Sember
Name:
Michael T. Sember
Title: President and Chief Executive Officer
Dated: December
9, 2005
Exhibit
Index
Exhibit
Number Description
of Exhibits
99.1 Press
Release of Registrant dated December 9, 2005